Global Market Access Director, Gene Therapy

Initial Therapeutics, Inc.; Boston (MA); On-site; USD 182,000 - 266,000; Full time

Benefits offered by this job

Bonus eligibility

Job summary

Lilly is seeking a Senior Director, Market Access to own the global strategy for pricing and access across gene therapy assets. The role drives one global frame and partners with LV&A and IVA to tailor locally, shaping policies and payer negotiations worldwide.

Responsibilities include building standardized payment models, developing the value dossier narrative, and ensuring cross-asset coherence across markets. Travel 10-20% is expected.

Qualifications

• Bachelor's degree.
• 10+ years of progressive market access, pricing, or payer strategy experience in biopharma.
• Working knowledge of payer, HTA, and reimbursement systems in major international markets.
• Experience building a pricing, access, or contracting framework from scratch.

Responsibilities

• Build one global pricing and access framework — value-driver logic, utility, and framing for novel contracting approaches.
• Establish access positioning for assets ahead of pivotal readouts and launches, with early alignment to LV&A and IVA.
• Decide asset-by-asset what global position elements stay versus local customization.
• Partner to execute pilots that advance Lilly’s market access capabilities.
• Own the strategic narrative and evidence prioritization behind each asset's global value dossier.
• Represent LRM in external forums shaping policy for cell and gene therapies.

Skills

Global pricing

Pricing & contracting

Payer policy engagement

External representation

Cross-asset coherence

Education

Bachelor's degree

Job description

Lilly is seeking a Senior Director, Market Access to own the global strategy for pricing and access across gene therapy assets. The role drives one global frame and partners with LV&A and IVA to tailor locally, shaping policies and payer negotiations worldwide.

Responsibilities include building standardized payment models, developing the value dossier narrative, and ensuring cross-asset coherence across markets. Travel 10-20% is expected.